

Sheet

1

of

1

PTO/S8/DBA: (07-05)
Approved for use through 07/16/2006. OMB 0551-0310
U.S. Pattent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a Condition of Horman unless to contriber a valid OMB corter (or the

64301(46590)

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many she ets as necessary)

Live as many she ets as necessary)

Substitute for form 1449A/B/PTO

Complete if Known
Application Number

10/552,340

Filing Date
Cochoer 6, 2005

Fist Named Inventor
Toshihiro Yamamoto
Al Unit
N/A
Examiner Name
Not Yet Assigned

Attorney Docket Number

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number-Kind Code ² (#known)						
$\overline{}$	AA*	US-5,643,911-A						
	AB*	US-5,324,727-A						
	AC*	US-5,089,494-A						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳			
	BA	JP-10-109936-A				1			
	BB	JP-2-129180-A				٧			
	BC	JP-62-228067-A				V			
	BD	WO-01/89517							

"EXAMINED. Initial *returnor consistent, whether or not detain is a conformance with MFEP 800. Once line through obtains it not in continuous and not consistent. All the copy of this form when recommunication be paperant. "CET RO. These applications when when the man state is required to the Cile. No. see not impossing when a mind with men striple settings of the continuous and the continuo

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Cite No.1 Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), title of the item imagazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.			
	CA	G. Cheng et al., Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5, Gene, 2001, 269(1-2), 131.	Г		
	СВ	S. Shimohama et al., Activation of NADPH Oxidase in Alzheimer's Disease Brains, Biochem. Biophys. Res. Commun. 2000, 273(1), 5.			
	СС	S. DeAtley et al., Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture, Toxicology, 1999 May 3, 134(1): 51-62.			
	CD	T. Münzel et al., Evidence for Enhanced Vascular Superoxide Anion Production in Nitrate Tolerance, J. Clinical Investigation, 1995, 187-194.			
	CE	K. Griendling et al., NAD(P)H Oxidase Role in Cardiovascular Biology and Disease, Circ-Res. 2000, 86, 494-501.			
	CF	Bayraktutan et al., Expression of a functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells, Cardiovascular Research, 1998, 38, 256-262.			
	CG	Y. Li et al., Diphenyleneiodonium, an NAD(P)H Oxidase Inhibitor, also Potently Inhibits Mitochondrial Reactive Oxygen Species Production, Biochem. Biophys. Res. Commun. 1998, 253, 295.			
	СН	A. Cayatte et al., S17834, a New Inhibitor of Cell Adhesion and Atherosclerosis that Targets NADPH Oxidase, Arterioscler. Thromb. Vasc. Biol., 2001, 21:1577.			
	CI	M. Geiszt et al., Chronic granulomatous disease: more than the lack of superoxide? J. Leukoc. Biol. 2001, 69, 191.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Craig Ricci/	Date 03/30/2009 Considered	